Silence Therapeutics (NASDAQ:SLN) Price Target Lowered to $3.00 at The Goldman Sachs Group

Silence Therapeutics (NASDAQ:SLN) had its price target decreased by The Goldman Sachs Group from $4.00 to $3.00 in a research note issued to investors on Friday,Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

Several other equities analysts have also issued reports on SLN. Morgan Stanley lowered their target price on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a report on Friday. Chardan Capital reduced their price objective on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a research report on Friday. BMO Capital Markets dropped their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 7th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.

Silence Therapeutics Trading Up 3.9 %

SLN opened at $3.70 on Friday. The company has a market cap of $110.74 million, a price-to-earnings ratio of -2.36 and a beta of 1.20. The stock has a fifty day simple moving average of $3.39 and a two-hundred day simple moving average of $6.57. Silence Therapeutics has a 12-month low of $1.97 and a 12-month high of $24.38.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative return on equity of 62.81% and a negative net margin of 342.00%. The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $3.58 million. On average, analysts predict that Silence Therapeutics will post -1.77 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC raised its position in shares of Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock valued at $7,222,000 after purchasing an additional 849,676 shares during the period. Redmile Group LLC increased its stake in Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after buying an additional 500,000 shares in the last quarter. Bank of America Corp DE raised its holdings in Silence Therapeutics by 48,165.6% during the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company’s stock valued at $3,434,000 after acquiring an additional 498,032 shares during the period. Marshall Wace LLP lifted its position in shares of Silence Therapeutics by 190.3% in the fourth quarter. Marshall Wace LLP now owns 488,889 shares of the company’s stock valued at $3,364,000 after acquiring an additional 320,472 shares in the last quarter. Finally, Cantor Fitzgerald L. P. lifted its position in shares of Silence Therapeutics by 61.5% in the fourth quarter. Cantor Fitzgerald L. P. now owns 539,726 shares of the company’s stock valued at $3,713,000 after acquiring an additional 205,534 shares in the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.